Predict your next investment

Venture Capital

See what CB Insights has to offer

Investments

7

About Bionova Capital

Bionova Capital is a privately held Asset Management company focused on the healthcare sector. As a venture capital investor, it specializes in identifying and investing in high-potential seed/early-stage investment opportunities that provide medical device, medical technology, diagnostic, chronic disease monitoring, IT-integration opportunities.

Bionova Capital Headquarter Location

Estrada do Paço do Lumiar Campus do Lumiar

Lisboa, 1649-038,

Portugal

+351 21 982 9000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Bionova Capital News

SolasCure announces £15m Series A raise

Aug 10, 2021

SolasCure announces £15m Series A raise Investors in this round: BRAIN Biotech AG, EVA Pharma, Bionova Capital, Seneca Partners, Development Bank of Wales, Private investors Biotech start-up SolasCure has announced the completion of its Series A investment round, to support the development of their wound cleaning product, Aurase®. The Cambridge based biotech company has successfully completed its Series A raise of £15m, with funding from industry veterans, institutional venture, and strategic investors. SolasCure is developing proprietary technology leveraging biomimicry and evidence-based medicine to empower health care professionals to treat patients with chronic wounds. Their first investigational product, Aurase®, is a hydrogel containing an enzyme cloned from medical maggots that can be used to support healthcare professionals treating patients with chronic wounds. Speaking upon the completion of the round, Dr Sam Bakri, Founder and CEO of SolasCure said: “We are delighted to have completed our Series A round, which will help us to move onto the clinical trial stages of product development. We are excited to be working with such knowledgeable and specialist investors, as they join us on our mission to support healthcare professionals with wound care products that significantly improve the health and wellbeing of patients with chronic wounds.” The raise began with investment from BRAIN Biotech AG (Xetra:BNN), who are SolasCure’s largest shareholder. Adriaan Moelker, CEO BRAIN Biotech AG, said: “It has been an encouraging sign for all partners that SolasCure has been able to successfully close another financing round with rising pre-money valuation during the pandemic. We continue to be committed to support SolasCure on its way to market for the innovative wound debridement enzyme Aurase®.” The round was completed following investment by Seneca Partners, an investment management business based in the UK. Speaking on their investment, Matt Currie, Investment Director at Seneca said: “We are delighted to support SolasCure as part of this latest funding round. The team they have brought together are truly world-class, producing ground-breaking work in the wound care sector. Practitioners are crying out for a high-quality solution that can be transported, stored, and administered in an efficient and effective way, something severely lacking in the treatments available at present. We believe SolasCure’s Aurase product has the potential to become the go-to solution in this space”. In addition to the investments from BRAIN Biotech AG and Seneca Partners, other notable investors to date include Bionova Capital, experienced entrepreneur and life sciences angel investor Jonathan Milner (founder of Abcam), strategic investor EVA Pharma, the Development Bank of Wales, as well as François Fournier (former lead of Smith & Nephew’s Advanced Wound Care division). The GS Verde Group acted as advisors to the fundraise. Privacy Overview This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful. Strictly Necessary Cookies Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings. Enable or Disable Cookies If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again. Enable All

Bionova Capital Investments

7 Investments

Bionova Capital has made 7 investments. Their latest investment was in SolasCure as part of their Series A on August 8, 2021.

CBI Logo

Bionova Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

8/10/2021

Series A

SolasCure

$20.76M

No

4

3/23/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

10/15/2018

Series A

Subscribe to see more

$99M

Subscribe to see more

10

1/1/2016

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

Other Investors

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/10/2021

3/23/2021

10/15/2018

1/1/2016

Round

Series A

Series B

Series A

Seed VC

Other Investors

Company

SolasCure

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$20.76M

$99M

$99M

$99M

$99M

New?

No

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

4

10

10

10

10

Bionova Capital Team

4 Team Members

Bionova Capital has 4 team members, including current Chief Executive Officer, Ricardo Perdigão Henriques.

Name

Work History

Title

Status

Ricardo Perdigão Henriques

Chief Executive Officer

Current

Peter Villax

Chief Executive Officer

Current

Miguel Calado

Chief Financial Officer

Current

Goncalo Rebelo de Andrade

Managing Director

Current

Name

Ricardo Perdigão Henriques

Peter Villax

Miguel Calado

Goncalo Rebelo de Andrade

Work History

Title

Chief Executive Officer

Chief Executive Officer

Chief Financial Officer

Managing Director

Status

Current

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.